Hhlr Advisors LTD. Buys Shares of 366,028 Maze Therapeutics, Inc. $MAZE

Hhlr Advisors LTD. bought a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 366,028 shares of the company’s stock, valued at approximately $10,922,000. Maze Therapeutics makes up about 1.3% of Hhlr Advisors LTD.’s portfolio, making the stock its 15th biggest position.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Royal Bank of Canada boosted its stake in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics during the 4th quarter worth approximately $43,000. California State Teachers Retirement System lifted its stake in Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after purchasing an additional 766 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Maze Therapeutics in the 2nd quarter valued at approximately $48,000. Finally, Ameritas Investment Partners Inc. boosted its position in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares in the last quarter.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock opened at $29.58 on Thursday. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -11.74 and a beta of 2.21. Maze Therapeutics, Inc. has a twelve month low of $13.67 and a twelve month high of $53.65. The company’s fifty day moving average is $28.64 and its 200 day moving average is $32.04. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). Sell-side analysts forecast that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Insider Activity

In related news, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the sale, the insider directly owned 26,250 shares in the company, valued at $717,675. This represents a 22.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the sale, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at $699,643.26. This represents a 59.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 108,110 shares of company stock valued at $3,057,531. Company insiders own 5.30% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Monday. BTIG Research reissued a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.